Abstract:Importance:Germline variants in the MC1R gene are common and confer moderate melanoma risk in those with varied skin types. Approaches to precision skin cancer prevention that include genetic information may promote risk awareness and risk reduction in the general population, including Hispanics.Objective:To examine prevalence of interest in and uptake of MC1R testing in the general population and examine patterns across demographic and skin cancer risk factors.Design, Setting, and Participants:A randomized clinical trial examined interest in and uptake of MC1R testing among patients at University of New Mexico General Internal Medicine clinics. Study participants were randomized to either a usual-care condition (National Cancer Institute skin cancer pamphlet for diverse skin types) or an MC1R test offer. Participants were registered clinic patients (≥6 months) and English or Spanish fluent. Of the 600 participants recruited to the overall trial, the present study included those 499 participants randomized to the MC1R test offer.Interventions:Participants were presented with the option to log onto the study website to read 3 educational modules presenting the rationale, benefits, and drawbacks of MC1R testing.Main Outcomes and Measures:Main outcomes include website log on (yes vs no), saliva test kit request (yes vs no), and saliva test kit return for MC1R testing (yes vs no). Demographic and skin cancer risk factors were examined as potential predictors of test interest and uptake.Results:Of the 499 participants (220 [44%] non-Hispanic white, 242 [48%] Hispanic, 396 [79%] female; mean [SD] age, 54 [14.3] years), 232 (46%) elected to learn about MC1R testing by logging onto the website; 204 (88%) of those who logged on decided to request testing; and 167 (82%) of those who requested testing returned the kit. The strongest predictors of website log on were race/ethnicity and education (non-Hispanic whites were more likely to log on [odds ratio for Hispanics vs non-Hispanic whites, 0.5; 95% CI, 0.3-0.7], as were more highly educated individuals [odds ratio for more than high school vs high school or less, 2.7; 95% CI, 1.7-4.3]). The strongest predictor of ordering the test was sunburn history (odds ratio, 5.4; 95% CI, 2.3-12.9 vs no sunburn history).Conclusions and Relevance:There were moderately high levels of MC1R test interest and uptake in this diverse sample. Addressing potential barriers to testing may be warranted as genomic information becomes integrated into general population approaches to the precision prevention of skin cancer.Trial Registration:ClinicalTrials.gov identifier: NCT03130569.

Genetic test reporting of CDKN2A provides informational and motivational benefits for managing melanoma risk

Genetic Test Reporting and Counseling for Melanoma Risk in Minors May Improve Sun Protection Without Inducing Distress

Genetic testing for familial melanoma

Changes in Skin Cancer-Related Behaviors, Distress, and Beliefs in Response to Receipt of Low- to Moderate-Penetrance Genetic Test Results for Skin Cancer Risk

Interpretation of Melanoma Risk Feedback in First-Degree Relatives of Melanoma Patients.

Attitudes toward genetic testing, family planning and preimplantation genetic testing in families with a germline CDKN2A pathogenic variant

Evaluating an approach for communicating integrated risk scores for melanoma

Estimating CDKN2A Mutation Carrier Probability among Global Familial Melanoma Cases Using GenoMELPREDICT.

Effects of risk counseling on interest in breast cancer genetic testing for lower risk women

Psychosocial and Cultural Determinants of Interest and Uptake of Skin Cancer Genetic Testing in Diverse Primary Care.

Comprehension of Skin Cancer Genetic Risk Feedback in Primary Care Patients.

Pediatric Melanoma in Melanoma-Prone Families.

Prevalence of CDKN2A, CDK4, POT1, BAP1, MITF, ATM, and TERT Pathogenic Variants in a Single-Center Retrospective Series of Patients With Melanoma and Personal or Family History Suggestive of Genetic Predisposition

Interest and Uptake of MC1R Testing for Melanoma Risk in a Diverse Primary Care Population A Randomized Clinical Trial

Genetic Counseling, Testing, and Family Communication Into Survivorship After Diagnosis of Breast Cancer

A Randomized Trial of Two Remote Healthcare Delivery Models on the Uptake of Genetic Testing and Impact on Patient-Reported Psychological Outcomes in Families With Pancreatic Cancer: The Genetic Education, Risk Assessment, and Testing (GENERATE) Study

P069 Familial malignant melanoma: CDKN2A mutation-positive family tree

Patterns and Sources of Information about Family Melanoma Risk among Melanoma Survivors.

Variation in Cutaneous Patterns of Melanomagenesis According to Germline CDKN2A/CDK4 Status in Melanoma-Prone Families.

Melanoma Prone Families with CDK4 Germline Mutation: Phenotypic Profile and Associations with MC1R Variants.

Family Risk Discussions after Feedback on Genetic Risk of Melanoma.